Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

Key Takeaways

• FDA approves Differin Epiduo OTC for ages 12+, expanding access
• First prescription‑strength retinoid/benzoyl peroxide combo now OTC
• Galderma leverages 15‑year clinical legacy to boost market share
• One‑pump daily regimen improves adherence and long‑term acne control
• Available summer 2026 at Walmart, Target, Ulta, Amazon

Pulse Analysis

The FDA’s green light for Differin Epiduo’s OTC transition reflects a broader industry trend of moving proven prescription therapies into the consumer market. Acne remains one of the most common skin conditions in the United States, driving a multi‑billion‑dollar market for both prescription and over‑the‑counter products. By allowing a 0.1% adapalene and 2.5% benzoyl peroxide formulation to be sold without a prescription, Galderma taps into a sizable segment of younger consumers who seek effective, dermatologist‑endorsed solutions but prefer the convenience of retail purchase.

Clinically, the dual‑active gel has demonstrated superior outcomes compared with either component alone, achieving up to a 70% reduction in inflammatory lesions by week 12 and maintaining roughly 65% improvement after a year of use. The Simulgel™ base stabilizes both actives, enhancing tolerability and supporting a once‑daily, one‑pump regimen that encourages consistent application—an essential factor for long‑term acne control. Early‑stage antimicrobial action begins on day one, while the retinoid component addresses pore turnover, offering a comprehensive, multimodal approach aligned with dermatology guidelines.

From a business perspective, the OTC launch positions Galderma to capture incremental revenue beyond its traditional prescription channel. Placement in high‑traffic retailers such as Walmart, Target, Ulta and Amazon expands brand visibility and leverages the growing consumer preference for pharmacy‑ready skincare. The move also reinforces Galderma’s integrated dermatology strategy, using its therapeutic portfolio to fuel growth in the skincare segment, and sets a precedent for future prescription‑to‑OTC conversions across its product line.